Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
87.54 EUR | -1.49% | -4.10% | -1.99% |
May. 28 | EU okays $1.5 bln state funded joint hydrogen project, $1.1 bln joint healthcare project | RE |
May. 27 | Sanofi Gets US FDA’s Priority Review for Expanded Use of Blood Cancer Drug Sarclisa | MT |
Sales 2024 * | 46.28B 50.23B | Sales 2025 * | 49.84B 54.1B | Capitalization | 111B 120B |
---|---|---|---|---|---|
Net income 2024 * | 7.08B 7.69B | Net income 2025 * | 8.7B 9.45B | EV / Sales 2024 * | 2.54 x |
Net Debt 2024 * | 6.68B 7.26B | Net Debt 2025 * | 2.28B 2.47B | EV / Sales 2025 * | 2.27 x |
P/E ratio 2024 * |
15.8
x | P/E ratio 2025 * |
12.8
x | Employees | 86,088 |
Yield 2024 * |
4.37% | Yield 2025 * |
4.6% | Free-Float | 87.13% |
Latest transcript on Sanofi
1 day | -1.48% | ||
1 week | -4.10% | ||
Current month | -5.25% | ||
1 month | -4.06% | ||
3 months | -0.55% | ||
6 months | +3.33% | ||
Current year | -1.99% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 19-08-31 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 21-12-31 |
Chief Tech/Sci/R&D Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 14-04-30 |
Lise Kingo
BRD | Director/Board Member | 62 | 20-04-27 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 20-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-29 | 88.04 | -0.92% | 120 |
24-05-28 | 88.86 | -1.00% | 290 |
24-05-27 | 89.76 | +0.12% | 360 |
24-05-24 | 89.65 | -1.80% | 153 |
24-05-23 | 91.29 | -0.56% | 120 |
Delayed Quote Deutsche Boerse AG, May 29, 2024 at 05:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.59% | 727B | |
+30.31% | 592B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.21% | 238B | |
+7.02% | 204B | |
-5.52% | 203B | |
-1.70% | 160B |
- Stock Market
- Equities
- SAN Stock
- SNW Stock